公立医院抗肿瘤药物可获得性与可负担性研究——基于江苏省公立医院典型调查的数据分析

Study on availability and affordability of anticancer drugs in public hospitals——Based on the data analysis of the typical survey of public hospitals in Jiangsu Province

抗肿瘤药物的可获得性和可负担性是关系民生的重大问题,本文从这两个方面出发,对江苏省6个城市30家公立医院的26种抗肿瘤药物采用世界卫生组织/国际健康行动机构(WHO/HAI)标准调查法进行分析,分析发现:一线用抗肿瘤药物可获得性及负担性较好,适应症窄的抗肿瘤药物可获得性较差,基因治疗的靶向药物可负担性不尽人意。与原研药(Originator brands,OBs)相比,仿制药(Lowest-priced genercis,LPGs)的可获得性与可负担性均相对较好,灾难性支出的发生率也相对较低。由此建议政府部门加快仿制药上市进程;继续推进专利期药物政府价格谈判,最大限度地让利于民;继续发挥临床药师作用,制定合理的治疗方案,促进合理用药。

The availability and affordability of anti-tumor drugs are major issues related to people’s livelihood. From these two aspects, this paper uses the International Health Action Organization(WHO/HAI)standard survey methodto analyze and finds that the first-line anti-tumor drugs have good availability and affordability,otherwisethe narrowly-adapted anti-tumor drugs have poor accessibility.Compared with Originator brands(OBs), the availability and affordability of generic-priced genercis(LPGs) arenot relatively goodbutalso the incidence of catastrophic expenditure is relatively low. Therefore, it is recommended that the government departments speed up the process of listing generic drugs;continue to promote the government price negotiations for patents during the patent period;continue to play the role of clinical pharmacists, formulate reasonable treatment programs.